Apr 23, 2020 / 02:00PM GMT
Felix Lauscher - Sanofi - Head of IR North America & Asia
Good morning and good afternoon to everyone on the call. I hope everyone is safe and remaining healthy. Thank you for joining us to review the Phase II results of our brain-penetrant BTK inhibitor '168. As usual, you can find the slides to this call on the Investors page of our website at sanofi.com.
Moving to Slide 2. I would like to remind you that information presented in this call contain forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. I refer you to our Form 20-F document on file with the SEC and also our Document d'Enregistrement Universel for a description of these risk factors.
With that, please advance to Slide 3. Our speakers today in the order of presenting are Bill Sibold, Executive Vice President, Specialty Care; Erik Wallström, Therapeutic Area Head, Neurology Development; Rita Balice-Gordon, Therapeutic Area Head, Neurologic and Rare Disease Research; and John Reed, Executive Vice President, Global Head of
Sanofi SA to Discuss Phase 2b Results Of The Investigational BTK Inhibitor ('168) In Relapsing Multiple Sclerosis Conference Call Transcript
Apr 23, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers